In case you were wondering: the 'rat model' market is worth $358 million globally
Projected to grow 9% (CAGR) through 2020
Laboratory rats are such a common element of drug research that the term is also used for those who work in the field. And while there are many, many drugs that showed promise during this form of animal testing but later failed (and despite the efforts of animal activists to restrict the activity), lab rats are still an essential tool for researchers. Marketsandmarkets, a Pune, India, market research firm, has just announced a study putting the overall business at $358 million in 2014, rising to $602 million by 2020.
And, just as, say, chromatographs come in varieties like liquid, gas, high-pressure and such, lab rats come in a growing variety of types: Inbred, outbred, hybrid, knockout, immunodeficient. Rat-related services include breeding, cryopreservation, quarantine, genetic testing, model in-licensing and others. Growth drivers include the introduction of transgenic rat models, ongoing preclinical activities in life sciences, personalized medicine and the biosimilars market. Major players in the US (the world’s largest market) include Charles River Laboratories, Taconic Biosciences and Covance.
Interestingly, the 9% CAGR is well above the 3-4% projected growth in human clinical trials—not sure what that implies! One other interesting take: the global rat-model market represents 1/1000th of the US pharma market. Information on the study is available here.
(Photo courtesy of Charles River Laboratories)
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
